SCHEMBL442115

SCHEMBL442115

CC1(C)OB(c2cnc(N)cn2)OC1(C)C

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ANPEP P15144 2/20 0.32
LAP3 P28838 2/20 0.32
LPL P06858 5/20 0.32
LIPG Q9Y5X9 5/20 0.32
P2RX7 Q99572 1/20 0.32
FFAR1 O14842 1/20 0.31
PDGFRB P09619 1/20 0.30
KDR P35968 1/20 0.30
AAK1 Q2M2I8 1/20 0.30
CA1 P00915 2/20 0.30
CA2 P00918 2/20 0.30
CA9 Q16790 2/20 0.30
CA12 O43570 1/20 0.30
CA3 P07451 1/20 0.30
CA4 P22748 1/20 0.30
CA6 P23280 1/20 0.30
CA5A P35218 1/20 0.30
CA7 P43166 1/20 0.30
CA14 Q9ULX7 1/20 0.30
CA5B Q9Y2D0 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10137329 0.78 P2RX7 (0.36) LPLLIPGP2RX7FFAR1MAPK1
SCHEMBL17667871 0.77 FFAR1 (0.34) LPLLIPGP2RX7FFAR1MAPK1
SCHEMBL14436244 0.76
SCHEMBL9940656 0.76 LPL (0.34) LPLLIPGP2RX7FFAR1PDGFRB
SCHEMBL9940554 0.74 LPL (0.30) LPLLIPGP2RX7
SCHEMBL22559000 0.74 LPL (0.35) LPLLIPGP2RX7FFAR1
SCHEMBL15467608 0.74 SIRT6 (0.40) LPLLIPGP2RX7
SCHEMBL13968378 0.74 USP30 (0.34) AAK1
SCHEMBL15181587 0.73 PDGFRB (0.33) PDGFRBKDR
SCHEMBL15647925 0.73 TRPV4 (0.32) LPLLIPGFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368104-A1 Novel Dialkoxynaphtho[2,3-C]Furan-1(3H)-One Derivatives and Pharmaceutical Composition For Preventing or Treating Respiratory Disease or SARS-COV-2 Infection Disease, Comprising Same DONG WHA PHARM. CO., LTD. (KR) 2024-11-07 US disclosed
US-20240174648-A1 Small Molecule Compound TECHNODERMA MEDICINES INC. (CN) 2024-05-30 US disclosed
WO-2024086790-A1 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-c]PYRIDINE COMPOUNDS AND DERIVATIVES AS USP1 INHIBITORS EXELIXIS, INC. (US) 2024-04-25 WO disclosed
WO-2022208382-A1 NOVEL DIALKOXYNAPHTHO[2,3-C]FURAN-1(3H)-ONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RESPIRATORY DISEASE OR SARS-COV-2 INFECTION DISEASE, COMPRISING SAME 동화약품주식회사 2022-10-06 WO disclosed
EP-3268373-B1 TRICYCLIC DLK INHIBITORS AND USES THEREOF HOFFMANN LA ROCHE (CH) 2022-04-27 EP disclosed
WO-2021078023-A1 SMALL MOLECULE COMPOUND 嘉兴特科罗生物科技有限公司 2021-04-29 WO disclosed
WO-2021078023-A1 SMALL MOLECULE COMPOUND 嘉兴特科罗生物科技有限公司 2021-04-29 WO disclosed
WO-2021057890-A1 2H-BENZOPYRAN DERIVATIVES AS CRAC INHIBITORS 南京明德新药研发有限公司 2021-04-01 WO disclosed
WO-2020227312-A1 SYNTHESIS OF CRAC CHANNEL INHIBITORS CALCIMEDICA, INC. (US) 2020-11-12 WO disclosed
CN-107406462-B Tricyclic DLK inhibitors and uses thereof 豪夫迈·罗氏有限公司 2020-11-10 CN disclosed
US-20100075965-A1 PI3 KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG 2010-03-25 US disclosed
US-20100075965-A1 PI3 KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG 2010-03-25 US disclosed
US-20100075965-A1 PI3 KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG 2010-03-25 US disclosed
EP-2114950-A2 PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE Genentech, Inc. (US) 2009-11-11 EP disclosed
US-20090253696-A1 SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. 2009-10-08 US disclosed
EP-1989201-A1 PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE Novartis AG (CH) 2008-11-12 EP disclosed
US-20080269210-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2008-10-30 US disclosed
WO-2008073785-A2 PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2008-06-19 WO disclosed
WO-2008009076-A2 SUBSTITUTED PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO disclosed
WO-2007095588-A1 PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2007-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368104-A1 Novel Dialkoxynaphtho[2,3-C]Furan-1(3H)-One Derivatives and Pharmaceutical Composition For Preventing or Treating Respiratory Disease or SARS-COV-2 Infection Disease, Comprising Same IL5, ACE2, IL15 ANPEP 792/4885LAP3 1207/4885LPL 3407/4885
US-20100075965-A1 PI3 KINASE INHIBITORS AND METHODS OF THEIR USE PIK3CA, PIK3CD, PIK3CB ANPEP 2814/4885LAP3 2103/4885LPL 1484/4885
US-20240174648-A1 Small Molecule Compound JAK1, JAK2, TYK2 ANPEP 3500/4885LAP3 4397/4885LPL 4884/4885
US-20090253696-A1 SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS PNPO, PNP, DPYD ANPEP 1217/4885LAP3 991/4885LPL 2868/4885
US-20080269210-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE PIK3CA, AKT3, PI4KA ANPEP 4851/4885LAP3 1963/4885LPL 1257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.